Recruiting Acute Myeloid Leukemia Studies in Buffalo
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukem...
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary obj...
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem...
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). T...
Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
A treatment cycle is 28 days for Cycle 1 and Cycle 2. Tagraxofusp will be administered at 12 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 5 consecutive days (or 5 doses over a period not to...
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs u...
About Acute Myeloid Leukemia Clinical Trials in Buffalo
Acute myeloid leukemia (AML) is a fast-growing cancer of the blood and bone marrow characterized by abnormal myeloid cells. It is the most common acute leukemia in adults. Treatment typically includes intensive chemotherapy and may involve stem cell transplant.
There are currently 7 acute myeloid leukemia clinical trials recruiting participants in Buffalo, NEW%20YORK. These studies are seeking a combined 1,299 participants. Research is being sponsored by Janssen Research & Development, LLC, Taiho Oncology, Inc., Debiopharm International SA and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Acute Myeloid Leukemia Clinical Trials in Buffalo — FAQ
Are there acute myeloid leukemia clinical trials in Buffalo?
Yes, there are 7 acute myeloid leukemia clinical trials currently recruiting in Buffalo, NEW%20YORK. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Buffalo?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Buffalo research site will contact you about next steps.
Are clinical trials in Buffalo free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Buffalo studies also compensate for your time and travel.
What acute myeloid leukemia treatments are being tested?
The 7 active trials in Buffalo are testing new therapies including novel drugs, biologics, and treatment approaches for acute myeloid leukemia.
Data updated March 2, 2026 from ClinicalTrials.gov